Exact Sciences Corporation

Good day and thank you for standing by. Welcome to the Exact Sciences Corporation second quarter 2021 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you will need to press star 1 on your telephone. Please be advised that today's call is being recorded. If you require any further assistance during the call, please press star zero. I would now like to hand the conference over to your speaker today, Ms. Megan Jones. Please go ahead, ma'am.

Thank you, Leah, and thank all of you for joining us for Exact Science's second quarter 2021 conference call. On the call today are Kevin Conroy, the company's chairman and CEO, Jeff Elliott, our chief financial and chief operating officer, and Jake Orville, general manager of our pipeline. Exact Sciences issued a news release earlier this afternoon detailing our second quarter financial results. This skin's release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Reconciliations to gap figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Folks can be accessed through our website. It is now my pleasure to introduce the company's chairman and CEO, Kevin Conroy.

Thanks, Megan, and thanks to everyone for joining us this afternoon. We tested 850,000 people in the second quarter with Cologuard Oncotype DX in our COVID test. The Exact Sciences team remained unwavering in their dedication to our mission and delivered record results for Cologuard and Oncotype. The team delivered in spite of limited sales force and in-person wellness visits due to COVID. Exact Sciences is a leader in advanced cancer diagnostics because of our people, our capabilities, our scientific platform, and our powerful brands. We will transform cancer care with our strong foundation in screening and precision oncology and our pipeline of innovative tests. We have a relentless focus on creating a great company culture with the best team. We are inspired to achieve our mission of cancer eradication. Because of this passion and engagement, Exact Sciences was recently certified as a great place to work for the third year in a row. Today, we will review our second quarter performance, third quarter and full year guidance, and our progress for 2021 priorities. Our CFO and COO, Jeff Elliott, will now review our financial results. Thanks, Kevin.